In addition, several case series have published good tolerability and response to this combination [22,23,24] and another phase-2 trial, VE-BASKET, demonstrated single agent efficacy of the BRAF inhibitor, vemurafenib, in BRAFV600E mutant cancers. Here, BRAF is linked to cancer.